Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;265(6):1381-1392.
doi: 10.1007/s00415-018-8850-7. Epub 2018 Apr 7.

Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia

Affiliations

Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia

Lize C Jiskoot et al. J Neurol. 2018 Jun.

Abstract

Introduction: We performed 4-year follow-up neuropsychological assessment to investigate cognitive decline and the prognostic abilities from presymptomatic to symptomatic familial frontotemporal dementia (FTD).

Methods: Presymptomatic MAPT (n = 15) and GRN mutation carriers (n = 31), and healthy controls (n = 39) underwent neuropsychological assessment every 2 years. Eight mutation carriers (5 MAPT, 3 GRN) became symptomatic. We investigated cognitive decline with multilevel regression modeling; the prognostic performance was assessed with ROC analyses and stepwise logistic regression.

Results: MAPT converters declined on language, attention, executive function, social cognition, and memory, and GRN converters declined on attention and executive function (p < 0.05). Cognitive decline in ScreeLing phonology (p = 0.046) and letter fluency (p = 0.046) were predictive for conversion to non-fluent variant PPA, and decline on categorical fluency (p = 0.025) for an underlying MAPT mutation.

Discussion: Using longitudinal neuropsychological assessment, we detected a mutation-specific pattern of cognitive decline, potentially suggesting prognostic value of neuropsychological trajectories in conversion to symptomatic FTD.

Keywords: Biomarkers; Cognition; Familial; Frontotemporal dementia; Longitudinal; Neuropsychological assessment; Presymptomatic.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

LCJ, JLP, LvA, LHM, LDK, ELvdE, EGPD, RT, RvM, JvS, EvdB, JMP report no conflicts of interest.

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Participant in- and exclusion and sample size per time point. Two controls were excluded as they had multiple cognitive disorders (≤ 2 SD below reference mean) on neuropsychological testing. Eight mutation carriers converted to clinical FTD within the study window. Their data were restructured, so that there were three time points: 4 years before symptom onset, 2 years before symptom onset and symptom onset. Four years before symptom onset, only data of six converters were available, as two mutation carriers converted between baseline and first follow-up. The data of converters were compared to, respectively, baseline, follow-up after 2 years and follow-up after 4 years in non-converters and healthy controls
Fig. 2
Fig. 2
Multilevel linear regression model displaying longitudinal decline (4 years, 2 years and after symptom onset) in composite domain z-score in the total group of converters (light green), MAPT converters (light blue dotted line), GRN converters (dark blue dotted line), non-converters (dark green) and healthy controls (black). Models are displayed per cognitive domain: a social cognition, b attention and mental processing speed, c executive functioning, d memory, e visuoconstruction, and f language. NB: the healthy controls have a mean z-score of zero by default as the z-scores of mutation carriers were based on that (raw score minus mean score of healthy controls, divided by the standard deviation of healthy controls). MAPT microtubule-associated protein tau, GRN progranulin

References

    1. Snowden JS, Pickering-Brown SM, Mackenzie IR, et al. Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain. 2006;129:3091–3102. doi: 10.1093/brain/awl267. - DOI - PubMed
    1. Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ. 2013;347:f4827. doi: 10.1136/bmj.f4827. - DOI - PMC - PubMed
    1. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477. doi: 10.1093/brain/awr179. - DOI - PMC - PubMed
    1. Seelaar H, Rohrer JD, Pijnenburg Y, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476–486. doi: 10.1136/jnnp.2010.212225. - DOI - PubMed
    1. Adenzato M, Cavallo M, Enrici I. Theory of mind ability in the behavioural variant of frontotemporal dementia: an analysis of the neural, cognitive, and social levels. Neuropsychologia. 2010;48:2–12. doi: 10.1016/j.neuropsychologia.2009.08.001. - DOI - PubMed

MeSH terms